Further to Aug's great find below...

Further to Aug's great find below
http://www.reuters.com/article/us-p...of-consumer-healthcare-business-idUSKBN1CF19M

FYI:

This Reuters article may be of interest as it discusses the possible divestiture of Pfizers Consumer Healthcare Business.
It may or may not occur, but I wonder how this could affect the OTC's being trialled by Pfizer? Advil is their biggest seller and no doubt one of the " interesting molecules" being tested.
$US 15 billion is a lot of money. Will the hydrotrope IP be more likely be sold because of this?
IMO this may not be very good news. If Pfizer is intending to sell off OTC assets next year then I really can't see why they would be spending money on a "line extension" for Advil and the other OTC product.
Of course if the in-house Pfizer trials have produced outstanding results then maybe Aug's Pfizer buy-out of the hydrotropes tech is a possibility, but as quoted in the last Annual Report the Pfizer trials performed "well" - which is hardly an overwhelming endorsement.
NFI really.